Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OST 122

Next Previous
Drug Profile

OST 122

Alternative Names: OST-122

Latest Information Update: 21 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncostellae
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antiulcers; Small molecules
  • Mechanism of Action Janus kinase 3 inhibitors; NUAK1 protein inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Inflammatory bowel diseases

Highest Development Phases

  • Phase II Colorectal cancer; Fibrosis
  • Phase I/II Ulcerative colitis

Most Recent Events

  • 27 Dec 2022 Oncostellae completes a phase Ib/IIa trial in Ulcerative colitis in Spain and Ukraine (NCT04353791)
  • 27 Feb 2020 OST 122 is available for licensing as of 27 Feb 2020. http://oncostellae.com/23-25-mar-2020-oncostellae-participates-at-the-bio-europe-partnering-conference-in-paris/
  • 27 Feb 2020 Phase-II clinical trials in Fibrosis, and Colorectal cancer in Spain (PO), prior to February 2020 (Oncostellae pipeline, February 2020)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top